The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer

• DOI: 10.1016/j.csbj.2021.09.029
• Publication Date: 2021-09-28T06:57:57Z
• Authors: Zuobing Chen; Canping Chen; Lin Li; Tianfang Zhang; Xiaosheng Wang
• Keywords: Chromosome instability; Immune checkpoint; Cancer Immunotherapy; Spliceosome

Alterations in the spliceosome pathway (SP) have been associated with diverse human cancers. In this study, we explored associations of SP activity various clinical features, anti-tumor immune signatures, tumor immunity-related genomic and molecular response to immunotherapies targeted therapies 29 cancer types from The Cancer Genome Atlas (TCGA) database. We showed that was an oncogenic signature, as evidenced by its hyperactivation invasive subtypes correlations unfavorable outcomes immunosuppression positive mutation burden (TMB) aneuploidy cancers, suggesting association instability. However, negative between independent TMB. Furthermore, supported had a correlation immunotherapy four cohorts treated checkpoint inhibitors. Moreover, elevated is correlated increased drug sensitivity for broad spectrum therapies. conclusion, biomarker response, prognosis, immunotherapeutic drugs pan-cancer.